Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice

X chromosome aneuploidies have long been associated with human cancers, but causality has not been established. In mammals, X chromosome inactivation (XCI) is triggered by Xist RNA to equalize gene expression between the sexes. Here we delete Xist in the blood compartment of mice and demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome (mixed MPN/MDS) with 100% penetrance. Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, and vasculitis. Xist-deficient hematopoietic stem cells (HSCs) show aberrant maturation and age-dependent loss. Reconstitution experiments indicate that MPN/MDS and myelofibrosis are of hematopoietic rather than stromal origin. We propose that Xist loss results in X reactivation and consequent genome-wide changes that lead to cancer, thereby causally linking the X chromosome to cancer in mice. Thus, Xist RNA not only is required to maintain XCI but also suppresses cancer in vivo.

[1]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[2]  A. Sandberg Cytogenetics of the mammalian X chromosome. Part B. X chromosome anomalies and their clinical manifestations. , 1983 .

[3]  R. Jaenisch,et al.  A shift from reversible to irreversible X inactivation is triggered during ES cell differentiation. , 2000, Molecular cell.

[4]  R. Jaenisch,et al.  Xist-deficient mice are defective in dosage compensation but not spermatogenesis. , 1997, Genes & development.

[5]  Katsuya Yamamoto,et al.  Acquired gain of an X chromosome as the sole abnormality in the blast crisis of chronic neutrophilic leukemia. , 2002, Cancer genetics and cytogenetics.

[6]  K. Heinonen,et al.  Acquired X-chromosome aneuploidy in children with acute lymphoblastic leukemia. , 1999, Medical and pediatric oncology.

[7]  A. Suttie Histopathology of the Spleen , 2006, Toxicologic pathology.

[8]  Jeannie T. Lee,et al.  Perinucleolar Targeting of the Inactive X during S Phase: Evidence for a Role in the Maintenance of Silencing , 2007, Cell.

[9]  M. Sur,et al.  Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. , 2012, Cell stem cell.

[10]  J. Strouboulis,et al.  Development of hematopoietic stem cell activity in the mouse embryo. , 1994, Immunity.

[11]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[12]  Mark Coles,et al.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre , 2003, European journal of immunology.

[13]  H. Willard,et al.  Absence of the XIST gene from late-replicating isodicentric X chromosomes in leukaemia. , 1994, Human molecular genetics.

[14]  Jeannie T. Lee Epigenetic Regulation by Long Noncoding RNAs , 2012, Science.

[15]  B. Johansson,et al.  The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. , 2010, Human molecular genetics.

[16]  Carolyn J. Brown,et al.  The human XIST gene: Analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus , 1992, Cell.

[17]  T. Misteli,et al.  Chromatin maintenance by a molecular motor protein , 2011, Nucleus.

[18]  A. Tefferi,et al.  Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management , 2013 .

[19]  J. Lawrence,et al.  The disappearing Barr body in breast and ovarian cancers , 2007, Nature Reviews Cancer.

[20]  Jeannie T. Lee,et al.  Polycomb Proteins Targeted by a Short Repeat RNA to the Mouse X Chromosome , 2008, Science.

[21]  Jeannie T. Lee Gracefully ageing at 50, X-chromosome inactivation becomes a paradigm for RNA and chromatin control , 2011, Nature Reviews Molecular Cell Biology.

[22]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[23]  S. Morrison,et al.  Supplemental Experimental Procedures , 2022 .

[24]  K. L. Moore,et al.  The Sex Chromatin in Benign Tumours and Related Conditions in Man , 1955, British Journal of Cancer.

[25]  Carolyn J. Brown,et al.  The human X-inactivation centre is not required for maintenance of X-chromosome inactivation , 1994, Nature.

[26]  W. Vainchenker,et al.  New mutations and pathogenesis of myeloproliferative neoplasms. , 2011, Blood.

[27]  K. Eggan,et al.  Erosion of dosage compensation impacts human iPSC disease modeling. , 2012, Cell stem cell.

[28]  Jeannie T. Lee,et al.  Detection of nascent RNA, single-copy DNA and protein localization by immunoFISH in mouse germ cells and preimplantation embryos , 2011, Nature Protocols.

[29]  R. Rowntree,et al.  X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells , 2008, Proceedings of the National Academy of Sciences.

[30]  D. Grignon,et al.  Novel Perspective: Focusing on the X Chromosome in Reproductive Cancers , 2003, Cancer investigation.

[31]  J. Bennett,et al.  Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach , 2009, Haematologica.

[32]  Terry Magnuson,et al.  Evidence of Xist RNA-independent initiation of mouse imprinted X-chromosome inactivation , 2009, Nature.

[33]  P. Roux‐Lombard,et al.  Malignant histiocytosis in the leukaemic stage: a new entity (M5c-AML) in the FAB classification? , 1994, Leukemia.

[34]  Jeannie T. Lee,et al.  YY1 Tethers Xist RNA to the Inactive X Nucleation Center , 2011, Cell.

[35]  J. Maciejewski,et al.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. , 2012, Seminars in oncology.

[36]  N. Debili,et al.  Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. , 2001, Experimental hematology.

[37]  A. Tefferi Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management , 2011, American journal of hematology.

[38]  Jeannie T. Lee,et al.  X chromosome dosage compensation: how mammals keep the balance. , 2008, Annual review of genetics.

[39]  A. Reeve,et al.  The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. , 2003, The Journal of urology.

[40]  V. Barak,et al.  [Male breast cancer]. , 1989, Harefuah.

[41]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[42]  R. Jaenisch,et al.  Two-Step Imprinted X Inactivation: Repeat versus Genic Silencing in the Mouse , 2010, Molecular and Cellular Biology.

[43]  G. Blobel,et al.  GATA Transcription Factors and Cancer. , 2010, Genes & cancer.

[44]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[45]  S. Rastan,et al.  Requirement for Xist in X chromosome inactivation , 1996, Nature.

[46]  R. Jaenisch,et al.  Conditional deletion of Xist disrupts histone macroH2A localization but not maintenance of X inactivation , 1999, Nature Genetics.

[47]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[48]  J. Rinn,et al.  Large non-coding RNAs: missing links in cancer? , 2010, Human molecular genetics.

[49]  J. Downing,et al.  Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. , 2004, The Lancet. Oncology.

[50]  D. Harrison Competitive repopulation: a new assay for long-term stem cell functional capacity. , 1980, Blood.

[51]  Debashis Sahoo,et al.  Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age , 2011, Proceedings of the National Academy of Sciences.

[52]  R. Jaenisch,et al.  Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for XInactivation , 2006, Molecular and Cellular Biology.

[53]  M. Pellegrini,et al.  X-inactivation in female human embryonic stem cells is in a nonrandom pattern and prone to epigenetic alterations , 2008, Proceedings of the National Academy of Sciences.

[54]  F. Bertucci,et al.  Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms , 2012, Genes, chromosomes & cancer.

[55]  M. Lyon Gene Action in the X-chromosome of the Mouse (Mus musculus L.) , 1961, Nature.

[56]  D. Huso,et al.  Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. , 2011, Blood.

[57]  C. Mecucci,et al.  Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature , 1995, British journal of haematology.

[58]  A. Wutz Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation , 2011, Nature Reviews Genetics.

[59]  J. Mcneil,et al.  XIST RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure , 1996, The Journal of cell biology.

[60]  G. Dewald,et al.  Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. , 1989, Cancer genetics and cytogenetics.

[61]  Prabhakar R. Gudla,et al.  Allele-specific nuclear positioning of the monoallelically expressed astrocyte marker GFAP. , 2008, Genes & development.

[62]  S. Nishikawa,et al.  In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. , 1992, Blood.

[63]  Chris Sander,et al.  CancerGenes: a gene selection resource for cancer genome projects , 2006, Nucleic Acids Res..